HU6

HU6
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole;
CAS Number	2231311-68-3;
PubChem CID	135205989;
Chemical and physical data
Formula	C11H9N5O7
Molar mass	323.221 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C(=CN=C1[N+](=O)[O-])COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-];

HU6 is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety." Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.^[1]^[2] A phase 2b trial was launched in late 2023.^[3]

References

^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041.
^ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X.
^ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.

[1] Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041.

[2] Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X.

[3] "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.

[1]

[2]

[3]